Navigation Links
Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock
Date:10/24/2007

inical trial in the United States of its lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies and products under development, the identification of lead compounds, the successful preclinical development of our products, the completion of clinical trials, the review process of the FDA, foreign regulatory bodies and other governmental regulation, and other factors described in our filings with the Securities and Exchange Commission. The statements are valid only as of the date hereof and we disclaim any obligation to update this information.

For additional information, contact Protalix BioTherapeutics at: investors@protalix.com


'/>"/>
SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pipette.com announces brand new ... and AccuPet brand of pipettes. Micropipettes are ideal ... less and are a great tool for molecular ... The micropipette promotions were designed to offer a ... to help customers find the right solution. Brands ...
(Date:9/17/2014)... A long-term retrospective study of breast ... via interstitial brachytherapy suggests that women younger than ... be suitable to receive the treatment. Current American ... patients in the "unsuitable" category for APBI. In ... Beaumont Health System,s Peter Y. Chen , ...
(Date:9/17/2014)... and PRINCETON, N.J. , ... OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to ... its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed today ... Exosomes & SingleCell Analysis Summit. On September ... Sciences will give a presentation entitled: "Exosomes: A Multiplexed ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 JH ... California showroom located in Irvine. JH Technologies, a ... imaging systems, recently announced an expanded partnership with Leica ... leading microscopes and image analysis solutions will be featured ... 2nd. The new showroom facility is located within ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3
... SAN DIEGO, Dec. 13 Neurocrine Biosciences,Inc. (Nasdaq: ... at its San Diego campus, as a part of ... and associated costs,and expenses after the setback on indiplon. ... "It is with great disappointment that we have to ...
... with drug-eluting,stents must take a combination of aspirin ... year, and possibly longer, after stent,implantation. This is ... today in the journals of the Society for ... (ACC), and,American Heart Association (AHA). To access the ...
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... it has,notified the Listing Qualifications Department at the ... 2007 annual stockholders meeting,to no later than April ... 2007 annual stockholders meeting,in August 2007. The meeting ...
Cached Biology Technology:Neurocrine Announces Work Force Restructuring 2Neurocrine Announces Work Force Restructuring 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 2PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 4Sinovac Requests Extension for Annual Shareholders Meeting 2
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
(Date:9/17/2014)... From accessible and affordable health care to reproductive ... depend on the ability of people to identify ... openly and respectfully, and find the most defensible ... practices to support these societal conversations?, The Hastings ... of Bioethical Issues have teamed up to publish ...
(Date:9/17/2014)... student have designed a device based on a shorebird,s ... dew., The device could provide water in drought-stricken areas ... Luo, professor in the Mechanical & Aerospace Engineering Department, ... of Engineering department, published "Bioinspired Plate-Based Fog Collectors" in ... Applied Materials & Interfaces journal. ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2
... - Eurofins MWG Operon, an expert in next generation sequencing ... libraries for sequencing with Roche GS FLX or Illumina HiSeq ... long paired end (LPE) libraries with different jumping distances (3 ... After sequencing, the resulting reads are assembled into large contigs ...
... of a TB Vaccine PDP, An Exhibitor,s Workshop at the ... 1:00-2:00 PM VENUE: 2011 AAAS ANNUAL MEETING, ,WASHINGTON CONVENTION ... an overview of the state of the global TB epidemic ... product development partnerships such as Aeras; and ways that scientists ...
... found attached to the foot of an ancient Egyptian mummy ... parts, says the scientist who tested replicas on volunteers. ... a three-part wood and leather artefact housed in the Egyptian ... Chester artificial toe on display in the British Museum, not ...
Cached Biology News:Mummies' false toes helped ancient Egyptians walk 2
... Rabbit polyclonal to Kv4.2 Immunogen ... KLH, corresponding to amino acids 23-43 of ... Cross-reacts with Rat.Expected to cross-react with Human ... with immunogen), Rabbit (100% identity with immunogen) ...
... 2 Alzheimer's disease (AD) patients with ... mutations in the presenilin proteins (PSEN1; PSEN2) ... disease-linked mutations result in increased production of ... of amyloid deposits found in AD brains). ...
See product name for description....
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Biology Products: